How To Save A Drug: Iressa’s Return Relied On Consistency Across Totality Of Evidence
Drug Review Profile of the second life of AstraZeneca’s Iressa shows how FDA adapts to imperfect but improving information without putting undue burden on sponsors – and how the agency recently applied a similar iterative approach to another EGFR inhibitor, Astellas and Genentech’s Tarceva.
You may also be interested in...
Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion
NDA and BLA submission news from our US FDA Performance Tracker.
Drug Review Profiles: Behind The Scenes At US FDA
A year in our long-running series of deep dives into FDA review documents.
US FDA's Search For Meaning: Interpretation Of Regulatory Language Can Inspire Conflict In Drug Reviews
The Pink Sheet's Drug Review Profile series illustrates the challenge of reconciling review realities and broad statutory directives.